...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Diagnostic and Prognostic Significanceof CA 19-9 as Tumour Markerin Pancreatic, Hepatobiliary andOther Gastrointestinal Cancer
【24h】

Diagnostic and Prognostic Significanceof CA 19-9 as Tumour Markerin Pancreatic, Hepatobiliary andOther Gastrointestinal Cancer

机译：CA 19-9诊断和预后意义作为肿瘤标志物胰腺，肝胆和其他胃肠癌

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The CA 19-9 antigen isolated by Koprowski and colleagues in 1979 is a lacto-N-fucopentaose II-like substance and one of the tumour-associated antigens present in serum in the mucin fraction. Close attention has been paid to the role CA 19-9 in the diagnosis of digestive tract tumours. In this study, serum analysis of CA 19-9 levels in 91 patients with gastrointestinal, hepatobiliary and pancreatic carcinoma was done. These data was used to evaluate the clinicians with adequate information on use of CA 19-9 as tumour marker- both diagnostic and prognostic.Aim: To study the role of tumour marker, CA 19-9 as a diagnostic and prognostic tool, and also to monitor the response of gastrointestinal, hepatobiliary and pancreatic cancer to treatment.Materials and Methods: This cross-sectional study was done on 91 cases of gastrointestinal, hepatobiliary and pancreatic carcinomas conducted in tertiary care hospital associated with medical college in Jamnagar, Gujarat, India were studied from September 2012 to March 2015 for two years and five months. The sample size was of 91 patients. Statistical method used was sensitivity, specificity, positive predictive value and negative predictive value. The material used was serum of the patient both pre as well as postoperatively and CalBiotech CA 19-9 Elisa Kit was used to determine the Value. The collected data were entered into Microsoft Excel spread sheet. The statistical methods used for variables were Mean and median along with Sensitivity and Specificity. Software used was a€?Epi Infoa€?, version 7.0.Results: Total 91 cases of gastrointestinal, hepatobiliary and pancreatic carcinomas were studied. Enzyme Linked Immunosorbent Assay (ELISA) was used preoperatively and post operatively to determine the CA 19-9 values in patients of gastrointestinal, hepatobiliary and pancreatic carcinomas. It was found that CA 19-9 is an important tumour marker with sensitivity of 76.31% and specificity of 73.33% for diagnosis of the gastrointestinal, hepatobiliary and pancreatic carcinoma. When aided with Fine Needle Aspiration Cytology (FNAC) and histopathological findings it helps in giving a sure shot diagnosis. It also provides useful prognostic information for the same.Conclusion: This study helps to understand the role of CA 19-9 as diagnostic and prognostic marker for pancreatic, hepatobiliary and gastrointestinal carcinomas.
机译：由koprowski和同事分离的Ca 19-9抗原是1979年的乳酸 - 粘曲线II样物质，以及在粘蛋白级分中存在的血清中存在的肿瘤相关抗原之一。在诊断消化道肿瘤的诊断中，已仔细注意的作用。在本研究中，完成了91例胃肠，肝胆碱和胰腺癌患者的CA 19-9水平的血清分析。这些数据用于评估临床医生，有关使用CA 19-9的充分信息作为肿瘤标志物 - 诊断和预测。研究肿瘤标志物，CA 19-9作为诊断和预后工具的作用，以及监测胃肠道，肝胆和胰腺癌治疗的响应。在印度康纳格尔医学院的第三次护理医院中，在91例胃肠道，肝癌和胰腺癌中进行了这种横截面研究2012年9月至2015年3月从2015年9月进行了两年，五个月。样品大小为91名患者。使用的统计方法是敏感性，特异性，阳性预测值和负预测值。使用的材料是患者的血清，术后和Calbiotech CA 19-9 ELISA试剂盒用于确定该值。收集的数据已输入Microsoft Excel Spread表。用于变量的统计方法是均值和中位数以及敏感性和特异性。所使用的软件是一个€？EPI Infoa€？，版本7.0.Results：研究了91例胃肠道，肝胆碱和胰腺癌。酶联免疫吸附测定（ELISA）术前使用，并在可操作地施用，以确定胃肠道，肝胆和胰腺癌患者的CA 19-9值。发现CA 19-9是一种重要的肿瘤标志物，敏感性为76.31％，特异性为73.33％，用于诊断胃肠道，肝胆和胰腺癌。当辅助细针抽吸细胞学（FNAC）和组织病理学发现时，它有助于给出诊断。它还提供有用的预后信息。结论：本研究有助于了解Ca 19-9作为胰腺，肝胆和胃肠癌的诊断和预后标志物的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号